At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14 enrolled
Drug / intervention
Anti-IgE antibody omalizumab or placebodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test
In Brief
A Phase 4 clinical trial evaluating Anti-IgE antibody omalizumab or placebo for Sinusitis. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSinusitis
CountriesUnited States
CollaboratorsGenentech, Inc., Novartis Pharmaceuticals
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2005
First PostedJul 2005
Primary CompletionMay 2007
Study CompletionJan 2009
TodayJul 2026
First PostedJul 7, 2005
Enrollment StartJul 1, 2005
Primary CompletionMay 1, 2007
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 21.0 years ago
Interventions
Anti-IgE antibody omalizumab or placebodrug
given subcutaneously oce or twice monthly depending on dose